The US Food and Drug Administration had directed manufacturers to display a warning on statins labels, stating that the drug was linked with confusion and memory loss. The FDA directive came on the back of case reports that linked statins use with a number of side effects.
Researchers led by Dr Karl Richardson and Dr Marisa Schoen reviewed over 25 randomized, controlled trials (RCTs) and cohort, case-control, and cross-sectional studies that studied the effect of statins on patients and found little or no evidence that the drug was linked with adverse cognitive function.
"Low-quality evidence suggested no increased incidence of Alzheimer disease and no difference in cognitive performance in procedural memory, attention, or motor speed. Moderate-quality evidence suggested no increased incidence of dementia or mild cognitive impairment, nor any change in cognitive performance related to global cognitive performance scores, executive function, declarative memory, processing speed, or visuoperception", the researchers wrote in their report.